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Reduction of active disease by preventive therapy has the potential to make an important contribution
towards the goal of tuberculosis (TB) elimination. This report summarises discussions amongst aWorking
Group convened to consider areas of research that will be important in optimising the design and
delivery of preventative therapies. The Working Group met in Cape Town on 26th February 2012,
following presentation of results from the GC11 Grand Challenges in Global Health project to discover
drugs for latent TB.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. The 2050 elimination goal
The Stop TB Partnership has set the goal of tuberculosis elimi-
nation (deﬁned as an annual incidence of fewer than one case per
million individuals) by 2050.1 Although this is an ambitious goal in
the context of global trends over recent decades, the required rate
of decline is broadly in line with successful TB control achieved inx: þ44 20 7594 3095.
obertson).
-NC-ND license.post-second world war Europe and North America. The current
global control strategy is guided byMillennium Development Goal 6,
which is to reduce the incidence of cases by 2015, and the Stop TB
Partnership target of halving 1990 prevalence andmortality rates by
2015. Historically, control efforts have prioritised identiﬁcation and
treatment of all cases of active TB, but this has been insufﬁcient to
interrupt transmission and there is a need to combine the existing
approach with new interventions that will reduce the development
of infectious cases by vaccination and preventive therapy.2 The
framework chosen by the United Nations to replace theMillennium
Development Goals after 2015 will be critical for TB control.3
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of the present document is to outline a research strategy that will
optimise the impact of therapeutic intervention during the phase of
infection prior to development of clinical TB.
Latent tuberculosis infection (LTBI) is currently deﬁned by
immunological sensitisation to Mycobacterium tuberculosis anti-
gens in the absence of clinical symptoms of disease. The relation-
ship of the immune response to the continued presence of live
bacilli is unclear. This description is applicable to one third of the
global population and encompasses a diverse spectrum of indi-
viduals at widely differing risk of developing active TB.5 While the
broad concept of a clinically “latent” phase of infection provides the
rationale underlying preventive therapy, effective implementation
will depend on stratiﬁcation of individuals on the basis of disease
risk rather than the presence or absence of an immune response.
We propose to use the term “subclinical tuberculosis” to denote at-
risk populations who would receive the greatest beneﬁt from
preventive therapy.
There is extensive evidence that preventive therapy can reduce
the incidence of future disease, and current WHO guidelines
strongly recommend that HIV-infected persons in whom active TB
has been excluded should receive isoniazid for at least 6 months,
and preferably 9months, as part of a comprehensive package of HIV
care.6 Addition of rifapentine allows an important reduction to
a three-month treatment schedule7 in HIV-negative individuals,
though the risk of reinfection imposes an obvious limitation on the
utility of preventive therapy in areas with high rates of trans-
mission.8 Current preventive therapy involves prolonged treatment
of large populations in order to prevent a relatively small number of
cases. For tractable integration into global strategies for TB control,
we need short, safe preventive treatments targeted at high-risk
populations.
The overall strategic requirements are:
 Strategies to identify groups with subclinical TB at high risk of
developing symptomatic infectious disease
 Short, simple therapeutic regimens to treat subclinical TB and
prevent the development of active disease
 Integration of preventive therapy with pre- and post-exposure
vaccination strategies
2. Widening the diagnostic net
The effectiveness of current control efforts is limited by
incomplete recruitment of infectious cases, thereby limiting their
impact on TB transmission. Prevalence surveys have shown that an
important proportion of infectious individuals with bacteriologi-
cally positive sputum do not experience symptoms of sufﬁcient
severity to prompt health-seeking behaviour.9e11 In the context of
HIV co-infection in high burden settings, the prevalence of
asymptomatic culture-positive TB can be as high as 8.5%.12
Improved recruitment of prevalent cases will require expansion
of the diagnostic net by increased social awareness of early symp-
toms as well as the incorporation of more ﬂexible diagnostic tests
into health care programmes.
Three broad criteria can be proposed as potential early markers
of disease risk. The ﬁrst is bacterial load. Potential biomarkers
include detection of bacterial components in systemic ﬂuids,
detection of antibodies, and detection of M. tuberculosis-speciﬁc T
cell responses based on novel phenotypic markers. These strategies
are being explored in the context of deﬁnitive diagnosis of active
disease, but may have alternative application as indicators of future
risk. A second approach could be based on molecular markers of
early pathology; for example, metabolic or proteomic disturbances
related to lung damage. Blood-based transcriptional proﬁling offersa novel approach with potential application in this context.13,14 The
third could be novel imaging modalities that reﬂect bacterial load
and early disease activity, which may provide important tools to
track hostepathogen interactions and to discover biomarkers for
different stages of infection.5 With an increasing knowledge of
systems immunology, it may be possible to identify immunological
biomarkers that are precursors of future pathology.15,16 In order to
achieve the desired levels of speciﬁcity it may be necessary to
combine multiple biomarkers, using mathematical modelling
approaches to determine the potential utility of combining tests
with lower levels of sensitivity and speciﬁcity in point-of-care tests.
Finally, we should anticipate that, as the prevalence of infection
declines as TB control moves towards the elimination goal, we may
need to translate increasingly sophisticated diagnostic tools from
research into practical application.
In summary, in order to identify individuals who would receive
maximum beneﬁt from preventive therapy, we need to identify
novel biomarkers, or combinations thereof, that provide informa-
tion about:
 Bacterial load
 Early pathology
 Phenotypic state of antigen-speciﬁc T cells
3. Bacterial physiology
An intuitive expectation is that clearance of the small numbers
of bacteria present prior to disease onset should require less
extensive treatment than active disease. The need for prolonged
preventive therapy is thought to reﬂect either sequestration of
bacteria in sites of low drug penetration, or transient periods of
persistence involving a physiological state that confers phenotypic
tolerance.5 Phenotypic tolerance can be induced in a variety of
in vitro culture systems inwhich bacterial replication is inhibited by
starvation, oxygen deprivation, or other means, and it is likely that
such systems are broadly reﬂective of the in vivo situation.
Stochastic persisters that express a drug-tolerant phenotype inde-
pendent of environmental signals have also been observed within
an otherwise logarithmically-growing population in vitro, although
their relevance to in vivo infection is unclear.17,18 Non-replicating
persistence under oxygen-starved conditions has been well-
characterised, and the observation that metronidazole e a drug
that has in vitro activity only under hypoxic conditions e can be
applied successfully as preventive therapy in a nonhuman primate
model19 provides compelling evidence that hypoxia contributes to
latent TB. Phenotypic tolerance is also observed during active
disease, and the distinction between subclinical infection and
active TB is best viewed as a quantitative difference in distribution
of bacterial phenotype and load rather than as a strict qualitative
difference between replicating and non-replicating states.5 A
consequence of this line of reasoning is that the targeting of
phenotypically tolerant populations is of equal importance for
improved preventive therapy and for shortening regimens applied
in the treatment of active disease.
While technical advances, particularly in the area of tran-
scriptomics, have allowed characterisation of M. tuberculosis in
mouse tissues and in human sputum,20,21 there is very little
information about the physiological state of bacteria within human
lesions. Studies of mycobacteria isolated directly from human
sputum surprisingly revealed that the organisms are phenotypi-
cally and transcriptionally similar to bacteria adapted to hypoxia
in vitro.20 This conﬂicts with the conventional view of the origin of
sputum-borne bacilli as emerging from rapidly replicating bacterial
populations at the cavity surface. Also contrary to conventional
wisdom, in sputum (and lesions including cavities) the bacilli are
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or within neutrophils.22 The extensive heterogeneity of cell types
and architecture that make up human TB lesions suggests a diver-
sity of microenvironments that are likely to induce a corresponding
heterogeneity in bacterial phenotypes.5 Understanding of myco-
bacterial physiology in vivo will depend on our ability to interpret
sparse experimental data using systems biology models that inte-
grate transcriptomic, proteomic, lipidomic and metabolomic
networks.23 This should be complemented by the use of appro-
priate experimental models in which methods not easily applied to
humans, such as reporter bacteria and tool compounds to assess
drug penetration and lesion targeting, can be exploited.
A characteristic of bacteria in the non-replicating hypoxia model
is that they survive with a marked reduction in their energy
reserves.24 Further reduction of low ATP levels by targeting of ATP
synthase provides an attractive rationale for the ability of TMC207
to kill non-replicating M. tuberculosis.25 Recent evidence suggests
that pyrazinamide, another drug with activity against non-
replicating populations, disrupts processes involved in trans-
lation,26 highlighting this as another potential area for drug
discovery.
Improved understanding of the physiology of M. tuberculosis in
human tissues will provide an important foundation for the
rational design of novel drugs and regimens for preventive therapy
and for treatment of active TB. This will depend on:
 Technologies that provide direct experimental information
about bacteria in lesions from patients
 The development of experimental models that accurately
recapitulate the clinical efﬁcacy of drugs
 Integrative systems biology models that allow reconstruction
of bacterial physiology from partial datasets
4. Drug discovery
Renewed efforts to discover novel anti-mycobacterial drugs over
the last decade have followed two approaches. The ﬁrst is based on
the screening of small molecule libraries for compounds with the
ability to kill mycobacteria, followed by identiﬁcation of molecular
targets using genetic tools such as re-sequencing of resistant
mutants. The second approach involves the initial application of
genetic tools to identify essential enzymes that are then used as
targets in high-throughput biochemical screens. The ﬁrst approach
has been more successful, with TMC207 and novel nitroimidazole
derivatives27 in early stage clinical development for drug-resistant
and drug-susceptible TB, and both showing promising activity
against non-replicating phenotypes. However, whole cell screens
generate only a small number of potent hits, along with a large
number of hits with moderate potency. To exploit the latter cate-
gory of compounds, bacterial cell death surrogates are needed
which are more tractable and informative than measurement of
colony forming units, and which can be applied in screens that
better model in vivo mycobacterial physiology to prioritize
compounds for follow-up by medicinal chemistry.
The failure of target-based drug discovery can be rationalised in
part by the difﬁculty of moving from hits with potent activity
against puriﬁed enzymes tomolecules that efﬁciently penetrate the
mycobacterial cell envelope. A second limitation is that the
conventional model, based on the assumption that inhibition of an
individual metabolic reaction will cause cell death, may not be
a complete description of the mode of action of effective anti-
bacterials.28 Bactericidal activity is likely to depend on the down-
stream consequences of an initial drugetarget interaction which
results in the generation of toxic intermediates that act as the true
effector molecules.29 The selection of targets based on anunderstanding of downstream consequences, rather than on simple
genetic evidence of essentiality, is likely to increase the produc-
tivity of target-based discovery. The availability of medicinal
chemistry resources and the early use of ‘proof of concept’ or tool
compounds in vitro and in appropriate animal models, will be key
in elucidating issues associated with permeability, efﬂux and target
cell metabolism.
In the mouse model, combined administration of novel combi-
nations such as TMC207 and pyrazinamide have a striking synergy
that allows a signiﬁcant reduction in the treatment time required
for sterilisation.30 These empirical ﬁndings highlight the impor-
tance of screening for positive and negative interactions between
old and new drugs in novel combinations and dosages. Under-
standing which model systems or in vitro tests predict synergies
that might translate into therapies for human disease will require
signiﬁcantly more effort. Consideration of combined activities and
synthetic lethality could usefully be incorporated into drug
discovery strategies, and early stage screening assays should be
developed that mimic in vivo conditions to identify candidates such
as pro-drugs with poor in vitro activity.
To accelerate the drug discovery pipeline, there is a need to
develop:
 Strategies for target selection based on an improved under-
standing of the cascade of biochemical events triggered by the
initial drugetarget interaction
 Molecular assays for mycobacterial cell death that can be used
to monitor realetime activity of drugs and prioritize hits
 Structure-based understanding of penetration and accumula-
tion of small molecules in tissues, lesions and bacteria
 Understanding of drugedrug interactions and mechanisms5. Moving drugs to the clinic
The clinical development of new antimycobacterials typically
involves evaluation in a mouse model followed by assessment of
early bactericidal activity in humans. In the conventional mouse
model, disease is associated predominantly with the presence of
intracellular bacteria in loosely structured lesions. This represents
only a portion of human pathology; in particular, it does not reca-
pitulate the heterogeneous microenvironments and bacterial
phenotypes characteristic of human granulomas or cavities. Early
bactericidal activity (EBA) measures the impact of drugs on bacteria
that contribute to sputum positivity and transmission, but provides
no information concerning their effect on closed lesions that are
likely to contribute to the requirement for prolonged therapy;
measuring EBA over extended times may help to address this
limitation. Thus, while it can be anticipated that mainstream drug
discovery efforts will generate new compounds with potential
application to preventive therapy, many opportunities will be
missed without alternative late preclinical and early clinical
screens.
The low-dose non-human primate model reproduces key
features of latent TB in humans (reactivation by anti-TNF anti-
bodies, for example) and has been used to compare drug activities
during preventive therapy.31 The model is expensive but, by
incorporating live imaging readouts, provides high value data that
closely parallel clinical studies. Extension from cynomolgus
macaques to smaller primates, such as marmosets, would make the
model more tractable by reducing the amount of drug that is
required for testing.
Serial live imaging by combined computed tomography (CT) and
positron emission tomography (PET) provides a comprehensive
analysis of the dynamics of TB lesions in patients and experimental
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drug exposure complements early bactericidal activity by dis-
tinguishing lesions that resolve quickly or slowly in response to
conventional or novel treatment regimens. Evidence from prelim-
inary studies shows that lesions can be imaged in individuals with
latent TB, suggesting that PET/CT could be used to deﬁne rapid
endpoints for early clinical trials of preventive therapy regimens.
Host markersmay be a simpleway to infer bacterial load as the host
responds to this assault, and to monitor the decline in load during
effective therapy; imaging studies may aid in the discovery of such
markers.
To evaluate the potential role of novel drug regimens in
preventive therapy, it will be necessary:
 To extend the use of experimental models that mimic human
subclinical TB
 To exploit live imaging technologies tomonitor effectiveness of
drugs in preclinical models and in clinical studies
 To identify biomarkers that reﬂect the declining bacterial load
in response to effective therapy6. Immune modulation
Modulation of the host response presents an important adjunct
or alternative alongside preventive therapy targeting the pathogen.
While there arewell-characterised examples of immunemodulation
that enhance progression to active disease e the use of anti-TNF
antibodies, HIV-mediated depletion of CD4 cells e there is no clear
proof-of-concept for beneﬁcial immune modulation during
subclinical TB. If protective immunity requires a balanced regulation
of multiple immune functions, it would be misleading to assume
that a negative impact associated with reduction in one component
should necessarily imply a positive outcome were this component
enhanced.16 For example, while the absence of IFNg is detrimental to
protection, increasing amounts of IFNgwill not necessarily correlate
with increased protection. There is some evidence that combining
antiretroviral therapy and isoniazid preventative therapy has
synergistic beneﬁts in preventing TB in HIV-infected people.32
Immune reconstitution in HIV-TB patients with a higher bacterial
load demonstrates the pathogenic potential of such an increase in
immune response, in the form of immune reconstitution inﬂam-
matory syndrome (IRIS).33 Therefore, the study of pathological and
protective immune restoration in TB-infected patients during anti-
retroviral therapy provides fertile ground to understand the differ-
ence between protective and pathological immunity.34
In principle, improved control of subclinical TB could be ach-
ieved by induction of an enhanced immune response to clear per-
sisting bacteria, or by boosting the existing immune response to
maintain its containment function. Clearance of persisting infection
might be achieved by transient stimulation of innate effector
functions, using small molecules to modulate intracellular path-
ways or by blocking of regulatory cytokines or co-stimulatory
molecules.35,36 An obvious concern with such an approach is the
risk that systemic activation of innate immune mechanisms may
result in collateral pathological damage. In contrast, it may be
possible to induce targeted dampening of innate immune cell
function to reactivate quiescent lesions by transient immune
modulation.37 This “wake ‘em and whack ‘em” strategy would have
to be carefully coordinated with delivery of anti-mycobacterial
drugs, and may have deleterious consequences in individuals
with high bacterial load or harbouring a drug resistant strain.
The rational design of strategies to boost existing immune cover
is frustrated by a lack of understanding of pathways (other than HIV
co-infection) that lead to immune breakdown and reactivation.Potential mechanisms include senescence or exhaustion of key T cell
populations, or an imbalance between activating and regulatory
circuits that control immune homeostasis and the balance between
inﬂammation and antimicrobial mechanisms.38 A series of booster
vaccines that enhance the CD4 and CD8 T cell responses that are
dominant in the natural response to infection are currently in clinical
trials to assess their prophylactic efﬁcacy in combination with
BCG.38,39 Initial safety trials have found no detrimental impact
associated with delivery of these vaccines to individuals with
evidence of prior immune sensitisation, and plans are underway to
test their ability to reduce reactivation or reinfection disease. Given
the likely complexity of the regulatory networks associated with
existing immune responses, an intriguing alternative vaccine
strategywould be to induce a de novo immune response, for example
by targeting antigens that are not well-recognised during the natural
immune process40; improved phenotypic characterisation of myco-
bacterial subpopulations in human lesions has the potential to
contribute to such an approach. The application of mathematical
modelling to these immunological systems may provide insights
that can assist in the prioritization of proposed interventions.41
Opportunities to combat subclinical TB by immune modulation
include:
 Evaluation of current booster vaccines in populations with
subclinical TB
 Development of vaccines targeting novel antigens and/or
immune mechanisms
 Development of immunomodulatory vaccines that alter
pathology, prevent disease progression, or achieve sterile
pathogen eradication
 Molecular deﬁnition of immune mechanisms of mycobacterial
killing
 Development of robust, well characterised preclinical models
of subclinical TB for comparative assessment of vaccines and
treatment modalities7. Coordination and networking
Despite the substantial global population of individuals with
subclinical TB, there are disturbingly few experimental techniques
that generate interpretable data concerning their immune status or
the physiological condition of the bacteria that they are harbouring.
There is very limited access to material from subclinical TB lesions,
and experimental models that reﬂect the human condition are
expensive and available only in highly specialised laboratories. To
promote effective research in this area, there is a need to support
research networks that link availability of samples from clinical and
experimental infection with expertise in novel technologies, and to
enhance partnerships between clinicians, experimentalists and
epidemiologists. Clinical trial sites need baseline support to main-
tain their operational capacity, and long-term cohorts to support
surveillance and related studies, such as biomarker discovery and
validation. Addressing the logistic constraints associated with
implementation of disease control programmes in often poorly
resourced societies will be critical to the success of any new
intervention to combat subclinical TB; notably, this offers an
important opportunity to improve social aspects of TB control such
as access to drugs and health care, as well as facilitating operational
research. The reduction of disease by preventive therapy has the
potential to make a signiﬁcant contribution to the goal of TB
elimination. This is not a simple undertaking, and will require
a vigorous response to the challenge of implementing a short, sharp
intervention that is targeted to at-risk groups and can be integrated
within the TB elimination strategy.
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